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1. Introduction 
The oral route of administration is considered as the most widely employed route of administration due to its wide 
range of advantages like stability, ease of administration, accurate dosage, self medication and patient compliance. Hence 
oral solid dosage forms are mostly preferred. Among all the dosage forms, the tablet dosage form is the most popular, 
because of ease of transportability and lower manufacturing cost
 
[1]. The disadvantage of oral dosage forms such as 
Dysphasia or difficulty in swallowing can be overcome by developing rapidly disintegrating and dissolving tablet dosage 
forms which dissolve in saliva and does not require water for swallowing
 
[2].  Recent development in novel drug delivery 
system to enhance the safety and efficacy of drugs during administration of conventional tablets led to the development of 
oral disintegrating tablets [3].  
United States Food and Drug Administration (FDA) defined ODT as “A solid dosage form containing medical 
substances or active ingredient which disintegrates rapidly usually within a matter of seconds when placed upon the 
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tongue” [4]. The disintegration time for ODTs generally ranges from few seconds to a minute [5].  
Atenolol is β1- cardio selective adrenergic receptor blocker, widely used in the treatment of hypertension, angina 
pectoris, arrhythmias and myocardial infarction
 
[6]. This is also used for prophylactic treatment of migraine. It was 
specifically developed to pass through the blood brain barrier.  Atenolol being a cardio selective beta blocker does not show 
adverse effects when given to patients suffering from bronchial asthma and diabetes mellitus [7]. Patient compliance is 
better with atenolol because it is given once a day. It is also used to treat other conditions including dysautonomia, anxiety 
and hyperthyroidism. It has been reported that atenolol undergo extensive hepatic first pass metabolism following oral 
administration and has shorter biological half-life of 6 – 7 hours with oral bioavailability of 50% [8]. There are only 
conventional tablets of atenolol in the market and administration of these tablets has been reported to exhibit fluctuations in 
the plasma drug levels results either in manifestation of side effects like nausea, diarrohea, ischemic colitis and mesenteric 
arterial thrombosis or reduction in drug concentration at receptor site.Therefore,the  main aim of the present research is to 
formulate oral disintegrating tablets of Atenolol  using a combination of super disintegrants such as Crosspovidone, Cross 
Carmellose [9]. 
 
2. Materials and Methods 
The active ingredient Atenolol was received as a gift sample from Yarrow Chem Products, Mumbai,India. 
Microcrystalline cellulose received from Otto Kemi, Mumbai, India. Cross Povidone and Cross carmellose sodium are the 
super disintegrants received from Yarrow Chem Products, Mumbai, India. 
  All the other ingredients used in the formulation are of pharmaceutical analytical grade. 
Table 1:-Formula of atenolol tablets 
Ingredients F1 (mg) F2 (mg) F3 (mg) Normal (mg) Control (mg) 
Atenolol 50 50 50 50 50 
Crospovidone & Croscarmellose Sodium 12 12 12 12 - 
Microcrystaline Sodium 108 108 108 108 120 
Mannitol 5 5 5 5 5 
Aspartame 15 15 15 15 15 
Magnesium Stearate 4 4 4 4 4 
Talc 6 6 6 6 6 
Total Weight 200 200 200 200 200 
2.1 Method 
2.1.1 Preparation of Co-processed Super-disintegrants [10]:- 
The Co-processed Super-disintegrants were by prepared solvent evaporation method. A blend of Croscarmellose 
Sodium and Crospovidone in the ratio of 1:1, 1:2 and 1:3 was added to 10ml of methanol. The contents of the beaker were 
mixed thoroughly and stirred continuously till most of the methanol evaporated. The wet coherent mass was granulated 
through #44 mesh sieve. The wet granules were dried in hot air oven at 60◦C for 20 minutes. The dried granules were 
passed through #44mesh sieve and stored in airtight container till further use. 
2.1.2 Preparation of tablets by Direct Compression Method [11]:- 
Fast dissolving tablets of Atenolol were prepared by Direct Compression Method. All the ingredients except 
granular directly compressible excipients were passed through #60mesh separately. Then the ingredients were weighed and 
mixed in geometrical order and compressed into tablets of 200mg by using 10-station Rotary minipress tablet machine.  
Figure 1: Stepwise process for direct compression 
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2.2 Evaluation of tablets 
2.2.1 Pre-compression characterization [12]:-  
Bulk density 
Bulk density of a powder is defined as the ratio of the mass of the powder and its bulk volume. For bulk density 
determination a weigh quantity of the powder material is introduce into a graduated measuring cylinder and volume of 
powder is determine. 
Bulk Density = Mass of the powder 
                     Bulk volume 
Granule density 
Granule density is the ratio of the mass of the granular powder and the volume occupied by the granular material 
together with its intra-particle spaces. 
Granule density = Mass of the granular powder 
                       Granule volume 
Tapped density 
For determination of the bulk density, a weigh quantity of the granular powder is introduced into a graduated 
measuring cylinder and is tapped mechanically either manually or using a tapping device till a constant volume is obtain 
Tapped density = Mass of the granular powder 
                           Tapped volume of granules 
Compressibility index or Carr’s index: 
                                                    Compressibility index = Tapped density-Bulk density 
                                                                                               Tapped density 
Where B is the freely settled bulk density of the granules, and T is tapped bulk density of the granules. 
Powders having Carr’s index greater than 25 is considered to have poor flowa and those powders having Carr’s 
index 15 has good flow. 
Angle of repose 
The angle of repose is determine by allowing mass of powdered to flow freely through an orifice from a certain 
height and form a conical heap on the horizontal surface. The angle of repose is determined by the formula 
tan θ=h/r 
Where, 
θ is the angle of repose, 
h is the height of the heap of powder and 
r is the radius of the base of the heap of powder. 
 
2.2.2 Post compression characterization 
Weight variation test [13]:  
20 tablets were selected randomly from each formulation and their average weight was calculated using digital 
balance. All the 20 tablets were weighed individually and compared with the tablet to meet USP specifications if no more 
than 2 tablets are outside the percentage limit and if no tablet differs by more than 2 times the percentage limit. 
 
Table 2:  Pharmacopeial specifications for tablet weight variation 
Average weight of tablets (IP) Average o weight of tablets (USP) Maximum % Difference allowed 
Less than 80 mg Less than 130 mg 10 
80 mg-250 mg 130 mg-324 mg 7.5 
More than 250 mg More than 324 mg 5 
Tablet Hardness
 
[14]:- 
   Tablet hardness is termed as crushing strength and resistance to friability to withstand mechanical shocks of 
handling in manufacture, packaging and shipping. This can be tested by using one of the following hardness testers
 [9]
 i.e.  
Monsanto hardness tester, Strong Cobb tester, Pfizer tester, Erweka and Varian tester. 
.Wetting time [15]:- 
    The wetting time of the tablets was measured by a simple procedure. A circular tissue paper of 10 cm diameter was 
placed in a Petri dish containing 10 ml of water containing Eosin blue. A tablet was carefully placed on the surface of tissue 
paper. The time required for developing blue colour on the upper surface of the tablet was noted as the wetting time. 
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Water Absorption Ratio [16]:- 
A piece of tissue paper folded twice was placed in small Petridish containing 6ml of water. A tablet was put on the 
paper and the time required for complete wetting was measured. The wetting tablet was then weighed. Water absorption 
ratio R, was determined using the equation 
R=10(Wa/Wb) 
Where, 
Wb is the weight of the tablet before water absorption, 
Wa is the weight of the tablet after water absorption. 
Friability [17]:- 
   It is used to measure the mechanical strength of tablets. Roche fribalator is used to determine the friability by 
following procedure.  
    Procedure: - Twenty tablets were weighed and placed in Roche Friabilator where the tablets were exposed to rolling and 
repeated shocks resulting from free falls within the apparatus. After 100 revolutions, tablets are removed, dedusted and 
weighed again. The friability was determined as the percentage loss in weight of the tablets. 
                     % Friability = (loss in weight / initial weight) *100 
In vitro dissolution studies
 
[18]:- 
Freshly prepared pH 6.8 phosphate buffer (900ml) was placed in each dissolution vessel of dissolution test 
apparatus (USP, II Paddle method). The tablets were placed in the dissolution medium. The temperature of the dissolution 
medium was maintained at 37±0.5˚c and the paddle was rotated at 50 rpm. Five ml samples were withdrawn. The sample 
volume was immediately replaced with the same volume of fresh media as when as a sample was taken. The samples 
withdrawn were filtered, diluted and estimated spectrophotometrically 
[16]
 at 225 nm. Cumulative amount of the drug 
released at each interval was calculated by using standard graph of Atenolol. 
 
3. Results 
Table 2:-Pre compression parameters 
Formulation 
Code 
Angle Of 
Repose 
Bulk Density 
(Gm/Ml) 
Tapped Density 
(Gm/Ml) 
Carr’s   Index 
(%) 
Hausner’s 
Ratio 
Flowability 
F1 24.98 0.276 0.285 10.25 1.11 Excellent 
F2 26.88 0.267 0.307 13.08 1.12 Good 
F3 25.27 0.256 0.299 14.38 1.15 Good 
Normal 28.80 0.318 0.401 20.69 1.17 Good 
Control 29.62 0.320 0.400 20.00 1.18 Good 
 
Table 3:-Post compression parameters 
Formulation Code F1 F2 F3 Normal Control 
Weight Variation Pass Pass Pass Pass Pass 
Hardness (kg/cm
2
) 2.66 2.66 2.66 3.40 4.50 
Friability (%) 0.413 0.433 0.437 0.465 0.524 
Water Absorption Ratio (%) 25.22 24.10 22.90 8.40 5.59 
Wetting Time (sec) 120 150 135 210 300 
 
Table 4:- In-vitro dissolution data of co-processed super-disintegrant formulations of atenolol 
 
TIME (min) 
Cumulative percentage drug release 
F1 F2 F3 
1 73.4 73.2 72.6 
2 84.3 83.7 79.6 
3 85.0 84.3 80.8 
4 94.5 90.8 89.5 
5 97.7 97.2 94.4 
6 99.5 98.7 97.9 
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Figure 2: Dissolution profiles 
 
 
4. Discussion 
Atenolol Oral dispersible tablets were developed with an aim to improve patient’s compliance. The development 
was initiated with standard calibration curve using UV spectrophotometric methods for analysis of the drug. The UV 
spectrophotometric method was developed in 0.1N HCl at 225nm. The method shows linearity in the concentration range of 
5-40µg/ml with a correlation coefficient of 1. 
The Atenolol Oral disintegrating tablets were developed by co-processing of super disintegrants such as 
Crosspovidone, and Cross carmellose sodium in the ratios 1:1, 1:2 and 1:3. All the 3 formulations prepared with different 
ratios of Crospovidone and Cross carmellose releases 90 to 100% of the drug within 6mins. Based on the physico chemical 
properties, in vitro drug release profile, water absorption ratio and wetting time F 1 containing Cross carmellose sodium 
and Cross Povidone in the ratio 1:1 is optimised as the best formulation. 
 
5. Conclusion 
Oral disintegrating tablets of Atenolol were successfully prepared by using different superdisintegrants by direct 
compression method. The present investigations helped in studying the effect of formulation process variables especially 
the concentration of different super disintegrants on the dispersion time and drug release profile. The rapid disintegration of 
Atenolol tablets formulated in this investigation may possibly help in administration of Atenolol in a more palatable form 
without water, thus, the “patient-friendly dosage form especially for geriatric, bedridden, and non cooperative patients 
which makes it a promising candidate for further studies, including stability studies, on the way to achieving intraoral 
formulations. 
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